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Abstract  
Objective: Unlike other inhibitors of apoptosis proteins (IAP), survivin is expressed during fetal development, cannot 
be detected in normal adult tissues, and is re-expressed in most of the common human cancers. However, the 
clinicopathological significance of the expression of survivin in human breast carcinoma has not been fully 
elucidated. Therefore, we examined the accumulation of survivin in pathological specimens of mammary gland 
diseases to identify new protein markers that may lead to improvements in patient management. 
Methods: We investigated the expression of survivin using immunohistochemistry in 180 cases of breast disease 
accessioned in the Department of Pathology, International University of Health and Welfare Hospital and Nissan 
Tamagawa Hospital between 2003 and 2013.  
Results: Ninety-eight out of 141 malignant tumor cases (69.5%) stained positive for survivin, with no significant 
staining being detected in the remaining cases. Staining for survivin was completely absent in the epithelial cells of 34 
of 39 cases of benign disease. No correlation was observed between the expression of survivin and major prognostic 
factors in breast carcinomas including patient age, tumor size, histological grade, axillary lymph node metastasis, 
local recurrence, and visceral metastasis status. However, a significant difference was observed in the expression of 
survivin between malignant and benign tumors and other benign diseases.  
Conclusion: The results of the present study suggest that the expression of survivin is strongly selective for cancer 
cells and may be useful for identifying and quantifying human breast cancer. 
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Introduction 
Survivin is a member of the inhibitor of apoptosis protein (IAP) gene family, which has been 
implicated in both the inhabitation of apoptosis and regulation of mitosis [1]. Survivin is associated 
with the microtubules of mitotic spindles and is expressed in the G2M phase of the cell cycle [2]. 
Disruption of the survivin-microtubule interaction leads to the loss of survivin function and increases 
the activities of proapoptotic caspases 3 and 7. Unlike other IAPs, survivin is expressed during fetal 
development, cannot be detected in normal adult tissues, and is re-expressed in most of the common 
human cancers [3, 4]. Several immunohistochemical markers, such as P-53, Ki-67, HER2/neu, EGFR, 
estrogen receptor, CK5/6, and E-cadherin, have been evaluated for the discrimination of breast 
proliferative lesions. The development of a novel biomarker to prevent subjective errors may be 
necessary to assist pathologists in making accurate diagnose. To confirm these possibilities, we 
examined malignant, premalignant, and benign diseases and determine the use of survivin expression 
in mammary gland diseases. We investigated the accumulation of survivin in pathological specimens 
of mammary gland diseases to identify new protein markers that may lead to improvements in patient 
management. 
Materials and methods 
Patients and tissue samples 
We identified 180 cases accessioned in the Department of Pathology, International University of 
Health and Welfare Hospital and Nissan Tamagawa Hospital between 2001 and 2013 lumpectomy 
specimens. Case histories were reviewed for age, tumor size, histological grading, lymph node 
metastasis, local recurrence, and visceral metastasis for the cancer patients. Patients were followed-up 
until 2014 and 74 for the patients with 141 breast carcinomas were available with 10-year follow-up 
data. The diagnosis of recurrent disease was based on clinical and radiological examinations, and was 
confirmed by the pathological findings. Survival time was defined as the period between the primary 
treatment and death in each case. Pathological diagnoses were assigned retrospectively according to 
the criteria adopted by the WHO classification
 
[6].  
Immunohistochemistry analysis 
Sufficient lumpectomy specimens of breast diseases remained in blocks to permit the cutting of 
additional sections for immunohistochemical staining. Representative blocks were then selected for 
immunostaining. Survivin was evaluated by immunohistochemical analysis using a specific antibody. 
We examined survivin (Monoclonal mouse, clone 12C4, dilution of 1:50, DAKO Japan) protein 
expression using a fully automated system(NICHIREI BIOSCIENCES INC. Histostainer 36A). 
Briefly, five μm-thick unstained sections were placed onto an electrostatically charged glass slide and 
baked to allow for tissue adherence. Each immunostained slide was evaluated for the overexpression 
of survivin in the cancer cells. Cases were considered to be survivin-positive if more than 1% of the 
cell showed cytoplasmic and/or nuclear staining. Negative controls were obtained by omitting positive 
controls. All histological findings and immunostains were initially reviewed and scored by 2 
pathologists (A.T. and H.K.).  
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Statistical analysis 
The Social Survey Research Information Co., Ltd. Toukei 2012 software for Windows was used for 
statistical analysis. A χ2 test was used to assess statistical associations among variables, and the 
Mann-Whitney test was used to compare means. The Kaplan-Meier method was used for survival 
analysis, and differences in survival were estimated using the log-rank test. Differences were 
considered significant when p was less than 0.01. 
Results 
Clinicopathological characteristics 
The clinicopathological characteristics of the 180 breast disease cases identified in this study are 
summarized in Tables 1, 2, and 3. There were 141 cases of malignant tumors. Among these, there 
were 110 cases of invasive carcinoma, no special type (IC), 4 of invasive lobular carcinoma, 22 of 
ductal carcinoma in situ (DCIS), and 5 of tumors of special type. There were 39 cases of benign 
diseases (24 fibroadenoma, 6 mastitis, 4 papilloma, 3 fibrocystic disease, and 2 phyllodes). We also 
selected 8 cases of usual ductal hyperplasia (UDH) and 11 of atypical ductal hyperplasia (ADH) 
accompanied by malignant mammary gland tumors in the same specimen. The respective lesion was 
used in the investigation. All patients were women with breast carcinoma, and their ages ranged from 
32 to 88 years (mean 59.7). The mean tumor size was 2.1 cm at the maximum diameter. The 115 
cases of invasive carcinoma were Elston and Ellis modified Bloom–Richardson grade 1 in 51 case, 
grade 2 in 25 cases, and grade 3 in 39 cases.  
 
Table 1 Relationships between the characteristics of carcinoma and the survivin marker 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
Excluding invasive lobular carcinoma and ductal carcinoma in situ from malignant tumor. 
 
 
 Survivin 
P value 
  Positive Negative 
No.( 141 carcinoma cases) 98 43  
Age 59.8 59.6 0.8436 
    
Size(cm)    
Tumor size 2cm≧ 51 27 
0.2372 
Tumor size 2cm< 47 16 
    
Histological grading (115 cases of invasive carcinoma*)  78 37  
Ⅰ 32 19 
0.5050 Ⅱ 17 8 
Ⅲ 29 10 
    
Lymph node metastasis (%) 21 (21.4%) 12 (27.9%) 0.4029 
Local recurrence (%) 6 (6.1%) 6 (14.0%) 0.2276 
Visceral metastasis (%) 18 (18.4%) 6 (14.0%) 0.5208 
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Table 2 Relationships between survivin expression in benign diseases vs malignant tumors 
 
 
Histological type No 
Survivin 
 Positive Negative 
P value  
(malignant vs benign) 
Malignant 
Invasive carcinoma, no special type (IC)   110 74 36 
<0.0001 
Invasive lobular carcinoma 4 2 2 
Neuroendocrine carcinoma 1 1 0 
Mucinous carcinoma 1 1 0 
Invasive micropapillary carcinoma 2 2 0 
Spindle cell carcinoma 1 0 1 
Ductal carcinoma in situ (DCIS) 22 18 4 
Total 141 98 43 
Benign 
Fibrocystic disease 3 1 2 
Fibroadenoma 24 3 21 
Phyllodes 2 0 2 
Papilloma 4 1 3 
Mastitis 6 0 6 
Total 39 5 34 
 
 
Table 3 Relationships between survivin expression in benign diseases vs UDH, ADH, DCIS, and IC. 
 
 
 
 
 
 
 
 
 
 
Relationship between the expression of survivin with the clinicopathological 
characteristics of human breast diseases 
The expression of survivin was observed in 98 of 141 cases of breast cancer (69.5％) and 5 of 39 
(12.8%) cases of benign tumors and other benign diseases (Table 1,2). The staining pattern of breast 
carcinoma was predominantly characterized by the nuclear staining of epithelial cells (Figure 1). Very 
weak cytoplasmic staining was observed in only 4 of the 9 other cases of benign diseases. The 
expression of survivin was significantly higher in IC, DCIS, and ADH than in the benign disease 
group. A correlation was not observed between the expression of survivin and UDH (Table 3).  
Correlations between the expression of survivin and major factors in breast carcinoma including 
Histological type No 
Survivin 
Positive Negative P value 
Benign disease   39 5 34  
Usual ductal hyperplasia (UDH) 8 2 6 0.7366 
Atypical ductal hyperplasia (ADH) 11 7 4 0.0020 
Ductal carcinoma in situ (DCIS) 24 19 5 <0.0001 
Invasive carcinoma, no special type (IC) 110 74 36 <0.0001 
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patient age, tumor size, histological grade, axillary lymph node, metastasis, local recurrence, and 
visceral metastasis status were examined. However, based on our results, survivin expression did not 
correlate with these prognostic factors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Carcinoma with strong nuclear reactivity in tumor cells to the survivin antibody scored as positive 
(400x). 
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Figure 2, 3 These graphs illustrate the findings of disease-free and overall survival rates among breast cancer 
patients staining positive for survivin. Kaplan-Meier survival curves are shown for disease-free survival (Figure 
2) and overall survival (Figure 3) rates. 
 
 
Follow-up data were available in 77 of the 141 patients diagnosed with breast carcinomas. Of these, 
17 died of the disease following the initial diagnosis of the primary lesion. Sixty patients were alive 
10 years after the initial diagnosis of the primary lesion.  The 10-year survival rate, when corrected 
for intercurrent deaths, was 13 (25.4%) for survivin positive patients and 4 (15.3%) for patients with 
survivin-negative tumors. A higher frequency associated with disease recurrence and death in 
survivin-positive patients (Figure 2, 3).  
Discussion 
A preliminary limited survey of previous studies indicated the differential expression of survivin in 
several types of cancers [3,4,7-9]. Similar to previous findings, in spite of histological variations in 
cancers, the expression of survivin was observed in the malignant cell components of most of our 
cases [4,5,7-21]. This result was in contrast to our benign disease control group, including 
fibroadenoma, mastitis, and fibrocytic disease, in which the expression of survivin was reduced or 
absent in the epithelial components. Al-Joudi et al recently described 382 women with invasive ductal 
carcinoma of the breast, and survivin was positive in 260 (68.1%) of these cases [17]. They 
emphasized the importance of detecting of survivin in breast carcinoma to aid in its diagnosis and 
confirm malignancy. However, they only examined the expression of survivin in cases of invasive 
ductal carcinoma of the breast and did not compare it with premalignant lesions, DCIS, or benign 
diseases. Based on our results compared with benign and malignant diseases, immunohistochemical 
staining for survivin, we agree with these conclusions. Therefore, using a protocol to detect the strong 
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expression of survivin may contribute to a histological diagnosis in mammary gland tumors. 
The expression of survivin has also been detected in DCIS as well as in invasive lesions in breast 
tumors. Okumura et al reported the expression of survivin in DCIS and microinvasive carcinoma of 
the breast [22]. In contrast to our results, the frequency of a positive expression ratio of survivin was 
significantly higher in microinvasive carcinoma than in DCIS. However, DCIS is considered to be 
distinct from IC because of the lack of stromal invasion and a good prognosis. However, once stromal 
invasion occurs in DCIS, the biological behavior of these tumors becomes as aggressive as that of IC. 
The significantly lower expression of survivin in UDH than in ADH, DCIS, and IC may be due to its 
non-neoplastic potential. The expression of survivin was even observed in ADH lesions, but not in 
non-neoplastic regions, which is consistent with its selective expression in transformed cells. In 
addition, the number of survivin-expressing cells increased when ADH progressed to DCIS and IC. 
Similar to our results, the expression of survivin in precancerous lesions has been reported in several 
organs, which suggests that its expression occurs in the early stage of malignant transformation 
[7-9,20]. Thus, the expression of survivin may be induced during the transformation from benign to 
malignant tumors in the breast. 
We demonstrated that the expression of survivin was not associated with prognostic factors (age, 
tumor size, histological grade, axillary lymph node metastasis, local recurrence, and visceral 
metastasis) or survival. The prognostic value of survivin has been reported in several studies on breast 
carcinoma [10-16,18-21]. Using immunohistochemistry staining, recent studies reported a correlation 
between the expression of survivin and clinicopathological parameters. However, the findings of 
previous studies on the association between survivin and the prognostic parameters of breast 
carcinoma patients were inconclusive or contradictory. Chu et al reported that the expression of 
survivin correlated with clinicopathological parameters [12]. However, it does not have significance 
as a marker for predicting overall or disease-free survival. Similar to their findings, Nassar et al 
reported that the expression of survivin correlated with histological parameters, but not with overall 
survival [19]. Kayaselcuk et al also reported that the expression of survivin did not correlate with any 
of the pathological parameters examined [13]. Furthermore, surviving did not correlate with local 
recurrence or distant metastasis. 
However, the prognoses of patients in our study were based on an analysis of small groups; 
therefore, the meaning of these results is inconclusive.  
This is the first study to compare the expression of survivin immunohistochemically between breast 
carcinoma and premalignant and benign mammary diseases with the aim that such information will 
provide a basis for studying the expression of survivin in the diseased breast. The results obtained 
with the survivin antibody suggest that survivin may be useful for identifying and quantifying human 
breast cancer. However, these results need to be replicated and expanded to more cases before any 
recommendations can be made for the use of this antibody in the routine identification of breast 
diseases.  
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